Pharmaceutical sponsor
Shanghai JMT-Bio Inc. Clinical Trials
Studies where Shanghai JMT-Bio Inc. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 27Valid MeSH Conditiongs
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
Use these resources to provide understandable information about this study to patients, families, and health care providers:
- Trial name
- NCT07840729
- Testing
- JMT206 injection, Semaglutide injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai JMT-Bio Inc.
Unresectable Locally Advanced or Metastatic Melanoma, Unresectable Locally Advanced or Metastatic Urinary Tract Tumors
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma and urinary tract tumors, aiming to evaluate the safety, tolerability…
- Trial name
- NCT07280832
- Testing
- JMT108
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
A Study of JMT203 in Patients With Cancer Cachexia
A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Cancer Cachexia, Colorectal Cancer Cachexia
- Trial name
- NCT06868849
- Testing
- JMT203 Injection
- Where
- China
- Volunteers
- 307 people
- Sponsor
- Shanghai JMT-Bio Inc.
HER2-positive Recurrent or Metastatic Breast Cancer
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
This study is a randomized, controlled, open-label, multicenter, phase II superiority clinical trial. The planned study population consists of participants with HER2-positive recurrent or metastatic breast cancer who have not…
- Trial name
- NCT07545044
- Testing
- JSKN003, Trastuzumab, Pertuzumab
- Volunteers
- 60 people
- Sponsor
- Shanghai JMT-Bio Inc.
Resectable HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and…
- Trial name
- NCT07441460
- Testing
- KN026, HB1801, Trastuzumab
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Shanghai JMT-Bio Inc.
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
SYS6090 Combination Therapy in Advanced Lung Cancer
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or…
- Trial name
- NCT07472647
- Testing
- SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel
- Volunteers
- 596 people
- Sponsor
- Shanghai JMT-Bio Inc.
Healthy Participants
Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants
A This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial. It aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single administration of…
- Trial name
- NCT07419698
- Testing
- JMT206
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Shanghai JMT-Bio Inc.
HER2-positive Colorectal Cancer
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and…
- Trial name
- NCT07384377
- Testing
- JSKN003, Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib.
- Volunteers
- 123 people
- Sponsor
- Shanghai JMT-Bio Inc.
Advanced Malignant Tumors
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108…
- Trial name
- NCT06877650
- Testing
- JMT108, Pembrolizumab, Ivonescimab
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Shanghai JMT-Bio Inc.
HER2-positive Gastric Cancer
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive…
- Trial name
- NCT07332533
- Testing
- KN026, Capecitabine, Enlonstobart
- Volunteers
- 490 people
- Sponsor
- Shanghai JMT-Bio Inc.